Cediranib falls short in phase III recurrent glioblastoma study: Commentary
Publication
, Journal Article
Friedman, HS
Published in: Oncology Report
January 1, 2011
Duke Scholars
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
January 1, 2011
Issue
JANUARY
Start / End Page
11
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Friedman, H. S. (2011). Cediranib falls short in phase III recurrent glioblastoma study: Commentary. Oncology Report, (JANUARY), 11.
Friedman, H. S. “Cediranib falls short in phase III recurrent glioblastoma study: Commentary.” Oncology Report, no. JANUARY (January 1, 2011): 11.
Friedman HS. Cediranib falls short in phase III recurrent glioblastoma study: Commentary. Oncology Report. 2011 Jan 1;(JANUARY):11.
Friedman, H. S. “Cediranib falls short in phase III recurrent glioblastoma study: Commentary.” Oncology Report, no. JANUARY, Jan. 2011, p. 11.
Friedman HS. Cediranib falls short in phase III recurrent glioblastoma study: Commentary. Oncology Report. 2011 Jan 1;(JANUARY):11.
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
January 1, 2011
Issue
JANUARY
Start / End Page
11
Related Subject Headings
- Oncology & Carcinogenesis